Intercept Pharma (ICPT) Misses Q3 EPS by 16c, Revenues Miss; Raises FY19 Ocaliva Net Sales Outlook
Tweet Send to a Friend
Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.59), $0.16 worse than the analyst estimate of ($2.43). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
